Paraytec unveils analytical detection technology

University of York spinout Paraytec Ltd unveiled its patented analytical detection technology to an audience of investors at the White Rose Bioscience Forum today (03 November).

The company’s UV absorbance detection products use of novel, miniaturised detectors that employ capillaries as sample vessels. The products offer greatly improved sensitivity and dynamic range and have a range of applications in industry and research, including UV absorbance measurements on nanolitre volumes (eg DNA, RNA proteins), clip on detectors for capillary separations and parallel UV characterisation of compound libraries.

The technology provides accurate measurements over a large dynamic range and uses real time UV imaging on moving biomolecules. It also uses an active pixel sensor array to monitor sample and reference beams.

Paraytec has already attracted strong interest from pharmaceutical companies and research institutions and is seeking investment in the region of £250K to develop its business model and manage the transition from prototypes to production.

Paraytec’s technical director, Professor David Goodall said: ”The market research we have conducted with end users has been extremely positive, and clearly shows that there is a strong market pull for Paraytec’s novel advances in UV absorbance detection.”

This is the first time the White Rose University Consortium Bioscience Forum has run an Investment Track. The track was run by Connect Yorkshire, an organisation that specialises in training and mentoring for technology companies seeking finance. It also organises Investment Conferences twice a year to bring technology companies together with investors.

Simon Browning, managing director of Connect Yorkshire said: “Paraytec’s technology meets specific market needs and its improved sensitivity and dynamic range make it attractive to a number of market sectors. From the interest that has already been expressed in this technology, it’s likely that Paraytec will have a hugely successful future.”

Simon Donoghue, acting chief executive of the White Rose University Consortium said: “The investment track has demonstrated to delegates the wealth of novel bioscience research being undertaken in the region. We hope that this opportunity will result in further funding for the companies allowing their technologies to be developed further.”